Evaluating the in vitro impact of fatty acid–binding protein 5 inhibition on bone marrow stromal cells and myeloma cells
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/bqun6434 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Ashlee Meczywor und 3 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Multiple myeloma is a type of blood cancer that involves the uncontrolled proliferation of plasma cells. Despite advances in therapy, the disease will relapse and become resistant to therapy. This creates an unmet need to develop new drugs for myeloma therapy. Obesity is a known risk factor for multiple myeloma, which motivated us to study the role of fatty acids and fatty acid binding proteins (FABPs) as a potential new treatment target. FABPs are a family of lipid carriers that facilitate the intracellular transport of fatty acids and play an important role in cellular signaling. Our lab has shown that patients with higher FABP5 levels display more aggressive multiple myeloma. We also determined the efficacy of first-generation FABP5 inhibitors in limiting myeloma cell growth. More recently studies have demonstrated second generation FABP5 inhibitors to be effective in resistant prostate cancer and liver cancer.
Zitieren
APA
Meczywor, A., Qiang, Y., Ojma, I., & Reagan, M. (2026). Evaluating the in vitro impact of fatty acid–binding protein 5 inhibition on bone marrow stromal cells and myeloma cells. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/bqun6434
Vancouver
Meczywor A, Qiang Y, Ojma I, Reagan M. Evaluating the in vitro impact of fatty acid–binding protein 5 inhibition on bone marrow stromal cells and myeloma cells. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/bqun6434
BibTeX
@article{Meczywor2026,
author = {Meczywor, Ashlee and Qiang, Yai-Wei and Ojma, Iwao and Reagan, Michaela},
title = {Evaluating the in vitro impact of fatty acid–binding protein 5 inhibition on bone marrow stromal cells and myeloma cells},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/bqun6434}
}
EUVIMED